JP2024538755A - がんを処置するための、抗ｐｄ－１抗体との組合せにおけるｐｄ－ｌ１及びｃｄ１３７に対する多特異性結合剤 - Google Patents

がんを処置するための、抗ｐｄ－１抗体との組合せにおけるｐｄ－ｌ１及びｃｄ１３７に対する多特異性結合剤 Download PDF

Info

Publication number
JP2024538755A
JP2024538755A JP2024521343A JP2024521343A JP2024538755A JP 2024538755 A JP2024538755 A JP 2024538755A JP 2024521343 A JP2024521343 A JP 2024521343A JP 2024521343 A JP2024521343 A JP 2024521343A JP 2024538755 A JP2024538755 A JP 2024538755A
Authority
JP
Japan
Prior art keywords
binding
heavy chain
antibody
binding agent
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024521343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538755A5 (https=
Inventor
ムイク，アレクサンダー
ネールムベルガー，クリスティーナ
ペンチェヴァ，ノラ
ジュレ－クンケル，マリア，エヌ，
サヒン，ウグル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Publication of JP2024538755A publication Critical patent/JP2024538755A/ja
Publication of JP2024538755A5 publication Critical patent/JP2024538755A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2024521343A 2021-10-06 2022-10-05 がんを処置するための、抗ｐｄ－１抗体との組合せにおけるｐｄ－ｌ１及びｃｄ１３７に対する多特異性結合剤 Pending JP2024538755A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163253106P 2021-10-06 2021-10-06
US63/253,106 2021-10-06
US202163257901P 2021-10-20 2021-10-20
US63/257,901 2021-10-20
PCT/EP2022/077749 WO2023057535A1 (en) 2021-10-06 2022-10-05 Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers

Publications (2)

Publication Number Publication Date
JP2024538755A true JP2024538755A (ja) 2024-10-23
JP2024538755A5 JP2024538755A5 (https=) 2025-10-14

Family

ID=84286302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024521343A Pending JP2024538755A (ja) 2021-10-06 2022-10-05 がんを処置するための、抗ｐｄ－１抗体との組合せにおけるｐｄ－ｌ１及びｃｄ１３７に対する多特異性結合剤

Country Status (10)

Country Link
US (1) US20240409653A1 (https=)
EP (1) EP4412714A1 (https=)
JP (1) JP2024538755A (https=)
KR (1) KR20240082387A (https=)
CN (1) CN119053340A (https=)
AU (1) AU2022360108A1 (https=)
CA (1) CA3233512A1 (https=)
IL (1) IL311901A (https=)
MX (1) MX2024004242A (https=)
WO (1) WO2023057535A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242827A1 (en) * 2024-05-22 2025-11-27 Genmab A/S Bispecific antibody against pd-l1 and cd137 in combination therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020263879A1 (en) * 2019-06-26 2020-12-30 Ap Biosciences, Inc. Antibodies for t-cell activation
WO2021156326A1 (en) * 2020-02-04 2021-08-12 Genmab A/S Antibodies for use in therapy
WO2022148410A1 (zh) * 2021-01-08 2022-07-14 北京韩美药品有限公司 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2259800T3 (es) 1990-06-11 2006-10-16 Gilead Sciences, Inc. Procedimientos de uso de ligandos de acido nucleico.
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
PT3514172T (pt) 2014-04-01 2020-04-21 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Imunorrecetores específicos de claudina-6 e epítopos de células t
WO2017209053A1 (ja) 2016-05-30 2017-12-07 アステラス製薬株式会社 新規な遺伝子組換えワクシニアウイルス
US20190185571A1 (en) 2016-07-28 2019-06-20 Musc Foundation For Research Development Methods and compositions for the treatment of cancer combining an anti-smic antibody and immune checkpoint inhibitors
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020263879A1 (en) * 2019-06-26 2020-12-30 Ap Biosciences, Inc. Antibodies for t-cell activation
WO2021156326A1 (en) * 2020-02-04 2021-08-12 Genmab A/S Antibodies for use in therapy
WO2022148410A1 (zh) * 2021-01-08 2022-07-14 北京韩美药品有限公司 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANTICANCER RESEARCH, vol. 35, JPN6025044766, 2015, pages 129 - 136, ISSN: 0005723739 *
CANCER IMMUNOL IMMUNOTHER, vol. 65, JPN6025044763, 2016, pages 1243 - 1248, ISSN: 0005723736 *
CANCER IMMUNOL RES., vol. 3, no. 2, JPN6025044765, 2015, pages 149 - 160, ISSN: 0005723738 *
GARRALDA E, ET AL.: "FIRST-IN-HUMAN PHASE I/IIA TRIAL TO EVALUATE THE SAFETY AND INITIAL CLINICAL ACTIVITY OF DUOBODY(R)-", J IMMUNOTHER CANCER, vol. Vol.8(Suppl 3):A412, JPN6025044762, 2020, pages 250 - 251, ISSN: 0005723735 *
HEPATOLOGY, vol. 71, no. 3, JPN6025044764, 2020, pages 955 - 971, ISSN: 0005723737 *

Also Published As

Publication number Publication date
KR20240082387A (ko) 2024-06-10
WO2023057535A1 (en) 2023-04-13
CN119053340A (zh) 2024-11-29
EP4412714A1 (en) 2024-08-14
US20240409653A1 (en) 2024-12-12
AU2022360108A1 (en) 2024-05-02
MX2024004242A (es) 2024-07-29
IL311901A (en) 2024-06-01
CA3233512A1 (en) 2023-04-13

Similar Documents

Publication Publication Date Title
JP7450592B2 (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
JP7809062B2 (ja) 療法において使用するための抗体
KR20220032642A (ko) 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
JP2019513008A (ja) Ｂｔｌａに対して特異性を有する抗体及びその使用
US20240327544A1 (en) Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
KR20230169135A (ko) 치료에 있어서 cd40 및 cd137에 대한 다중특이 결합제
US20250002600A1 (en) Multispecific binding agents against pd-l1 and cd137 in combination therapy
US20240409653A1 (en) Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers
US20240109972A1 (en) Antibody and taxane combination therapy
JP2023554422A (ja) がんの治療のための多重特異性抗体
US20240228578A1 (en) Cd80 extracellular domain fc fusion protein therapy
WO2025242827A1 (en) Bispecific antibody against pd-l1 and cd137 in combination therapy
JP2026513865A (ja) がんを処置するためのｐｄ－ｌ１およびｃｄ１３７に対する多重特異性結合剤
WO2024209072A1 (en) Multispecific binding agents against pd-l1 and cd137 for treating cancer
AU2023401158A1 (en) Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
CN117957253A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
CN118339183A (zh) 组合中针对pd-l1和cd137的多特异性结合剂
HK40110611A (zh) 癌症的组合治疗中针对cd40和cd137的多特异性结合剂
JP2024544518A (ja) 癌治療のためのｔｌｒ７アゴニストおよび組合せ
EA052230B1 (ru) Мультиспецифические связывающие агенты против cd40 и cd137 в комбинированной терапии
EA050156B1 (ru) Антитела для применения в терапии

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241002

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251001

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251001

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20251001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260210